Cantor Fitzgerald Analyst Dr. Caroline Corner Says Cerus INTERCEPT Platelet Approval Means Company Can Approach Any Center, Will Be Able To Ramp Rev. With 80% Blood Centers Signed Up; Says This Is Built Into Her Numbers